Effect of salvia miltiorrhiza pretreatment on the CCK and VIP expression in hepatic ischemia-reperfusion-induced digestive tract congestion

Abstract

The inhibitory effect of different reperfusion periods 45 min following hepatic ischemia on the expression of cholecystokinin (CCK) and vasoactive intestinal peptide (VIP) in the jejunum and the effect of salvia miltiorrhiza pretreatment were investigated, and the possible mechanism and implications were explored. Eighty rats were randomly divided into four groups: normal control group (CO group), sham-operated group (SO group), ischemia/reperfusion (I/R) injury group (IR group) and salvia miltiorrhiza pretreatment group (SM group). The rat model of I/R was established by using a non-invasive artery clamp to clip (45 min) or relax the hepatic pedicle. In the SM group, saline (40 mL/kg) and salvia miltiorrhiza injection (6 g/kg) were injected via the tail vein 30 min before clipping the hepatic pedicle. In the SO group only the porta hepatis was dissected after laparotomy without clamping the hepatic pedicle. At 0, 3, 12, 24 and 72 h post-reperfusion, respectively, upper jejunum samples were taken for immunohistochemistry of CCK and VIP. It was found that 0 h after I/R, the expression of CCK and VIP in the upper jejunum was upregulated. With prolongation of the reperfusion period, the expression of CCK and VIP was also increased, reached the peak at the 24th h, and gradually returned to the normal level at the 72nd h after reperfusion. The levels of both CCK and VIP in the SM group were lower than those in the IR group. It is suggested that the digestive tract congestion injury caused by liver ischemia can upregulate the expression of CCK and VIP in the jejunum following reperfusion. Salviae pretreatment can partly reduce the increased expression of CCK and VIP in the jejunum in the same period, which might contribute to the early recovery of gastrointestinal motility.

Keywords

hepatic ischemia-reperfusion / digestive tract congestion / cholecystokinin / vasoactive intestinal peptide / salvia miltiorrhiza

References

[1] LiuY P, LiuJ S. The progress of mechanism of liver ischemia-reperfusion. Linchuang Yanjiu Zazhi, 2008, 25(10): 1904–1907 (in Chinese)

[2] DeveyL, FerenbachD, MohrE, SangsterK, BellamyC O, HughesJ, WigmoreS J. Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism. Mol Ther, 2009, 17(1): 65–72

[3] TsungA, KluneJ R, ZhangX, JeyabalanG, CaoZ, PengX, StolzD B, GellerD A, RosengartM R, BilliarT R. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med, 2007, 204(12): 2913–2923

[4] ZhongZ, RamsheshV K, RehmanH, CurrinR T, SridharanV, TheruvathT P, KimI, WrightG L, LemastersJ J. Activation of the oxygen-sensing signal cascade prevents mitochondrial injury after mouse liver ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol, 2008, 295(4): G823–G832

[5] VardanianA J, BusuttilR W, Kupiec-WeglinskiJ W. Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med, 2008, 14(5–6): 337–345

[6] FuR, ShenH. A technical study on C-mean clustering segmentation for color immunohistochemical image based on matlab. Zhongguo Tishixue Yu Tuxiang Fenxi, 2007, 12(1): 6–10(in Chinese)

[7] ZhangN, TaoK, HuangT. Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line HT-29. J Huazhong Univ Sci Technolog Med Sci, 2007, 27(4): 399–402

[8] WanC, WangH, ChengR, GouS, LiuT. Effect of target-directed regulation of uncoupling protein-2 gene expression on ischemia-reperfusion injury of hepatocytes. J Huazhong Univ Sci Technol Med Sci, 2008, 28(5): 558–563

[9] ChenJ, WangG. Role of nuclear factor kappaB in intestine injury induced by hepatic ischemia reperfusion. J Huazhong Univ Sci Technol Med Sci, 2004, 24(3): 284–285, 291

[10] ZhangJ, WuH, WangL, ZhangJ, WangH, ZhengQ. TLR2 mRNA upregulation in ischemic lobes in mouse partial hepatic ischemia/reperfusion injury model. J Huazhong Univ Sci Technol Med Sci, 2004, 24(2): 144–146

[11] HuangC, ZhangZ, QiuF. Effects of 2-APB on store-operated Ca²⁺ channel currents of hepatocytes after hepatic ischemia/reperfusion injury in rats. J Huazhong Univ Sci Technol Med Sci, 2005, 25(1): 39–41

[12] CaiH, GuangY, LiuL. The protective effects of in vitro cultivated calculus bovis on the cerebral and myocardial cells in hypoxic mice. J Huazhong Univ Sci Technol Med Sci, 2007, 27(6): 635–638

[13] D'AlessioD. Intestinal hormones and regulation of satiety: the case for CCK, GLP-1, PYY, and Apo A-IV. JPEN, 2008,32(5): 567–568

[14] RaybouldH E. Mechanisms of CCK signaling from gut to brain. Curr Opin Pharmacol, 2007, 7(6): 570–574

[15] BernaM J, JensenR T. Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem, 2007, 7(12): 1211–1231

[16] MillerL J, GaoF. Structural basis of cholecystokinin receptor binding and regulation. Pharmacol Ther, 2008, 119(1): 83–95

[17] BaiJ, LüY, BaiQ. Construction of porcine CCK pDNA and its expression in COS-7 cells. J Huazhong Univ Sci Technol Med Sci, 2007, 27(3): 278–280

[18] TangM, NiH, XuL. Changes in the mRNA concentration of preprocholecystokinin in rat cerebral cortex and hippocampus after gastric distension. Acta Physiologica Sinica, 1999, 51(5): 488–494

[19] OnoueS, MisakaS, YamadaS. Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn Schmiedebergs Arch Pharmacol, 2008, 377(4–6): 579–590

[20] Masmoudi-KoukiO, GandolfoP, CastelH, LeprinceJ, FournierA, DejdaA, VaudryH, TononM C. Role of PACAP and VIP in astroglial functions. Peptides, 2007, 28(9): 1753–1760

[21] WatanabeS. Vasoactive intestinal polypeptide (VIP). Nippon Rinsho, 2005, 63(Suppl 8): 502–504

[22] ReichA, SzepietowskiJ C. Vasoactive peptides in the pathogenesis of psoriasis. G Ital Dermatol Venereol, 2008, 143(5): 289–298

[23] YoshiyamaM, de GroatW C. The role of vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide in the neural pathways controlling the lower urinary tract. J Mol Neurosci, 2008, 36(1–3): 227–240

[24] LangerI, RobberechtP. Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors. Biochem Soc Trans, 2007, 35(Pt 4): 724–728

[25] GongS, DingJ, ChangQ. The expression of VIP and SP in the cochlea of spontaneously hypertensive rats and its implication. J Huazhong Univ Sci Technol Med Sci, 2004, 24(4): 396–399

[26] MullerJ M, PhilippeM, ChevrierL, HéraudC, AlleaumeC, ChadéneauC. The VIP-receptor system in neuroblastoma cells. Regul Pept, 2006, 137(1–2): 34–41

Acknowledgements

This study was supported by the National Natural Science Foundation of China (Grant No. 30170928).

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg